Vietnam T-cell Therapy Market Size, Share, Trends and Forecast by Modality, Therapy Type, Indication, and Region, 2026-2034

Vietnam T-cell Therapy Market Summary:

The Vietnam T-cell therapy market size was valued at USD 18.87 Million in 2025 and is projected to reach USD 63.72 Million by 2034, growing at a compound annual growth rate of 14.48% from 2026-2034.

The Vietnam T-cell therapy market is currently gaining immense momentum due to the rising incidence of cancer, development of healthcare infrastructure, and government efforts to encourage the adoption of advanced cancer therapies. Increasing knowledge about the benefits of immunotherapy, rising investments in biotechnology research, and international collaborations are also fueling the adoption of this therapy. Improved regulatory policies and the development of dedicated treatment centers are also making the country an emerging destination for personalized cancer therapy, thus adding to the Vietnam T-cell therapy market share.

Key Takeaways and Insights:

• By Modality: Research dominates the market with a share of 74.3% in 2025, driven by extensive clinical trial activities, academic institution partnerships, and government funding for developing novel T-cell therapies addressing local cancer burden and treatment gaps.
   
• By Therapy Type: CAR T-cell based leads the market with a share of 65.0% in 2025, owing to demonstrated efficacy in treating hematologic malignancies, successful domestic treatment milestones, and increasing technology transfer from international partners.
   
• By Indication: Hematologic malignancies hold the largest share at 69.7% in 2025, reflecting established treatment protocols for leukemia and lymphoma, higher clinical success rates compared to solid tumors, and growing patient access to specialized oncology centers.
   
• By Region: Southern Vietnam comprises the largest region with 49.7% share in 2025, driven by concentration of advanced healthcare facilities in Ho Chi Minh City, presence of leading oncology hospitals, and higher population density requiring cancer treatment services.
   
• Key Players: Leading institutions drive the Vietnam T-cell therapy market through investments in cell and gene technology research, clinical trial partnerships with international organizations, development of domestic manufacturing capabilities, and collaborations aimed at reducing treatment costs while expanding patient access to advanced immunotherapy solutions.

The Vietnam market for T-cell therapy is developing as medical institutions, research centers, and government agencies begin to accept personalized cancer treatment solutions. The nation has shown considerable progress with successful CAR-T cell therapy treatment, including a historic case where the Vinmec Institute of Stem Cell Research and Gene Technology successfully treated a pediatric acute leukemia patient who attained complete remission after treatment. This milestone places Vietnam among the Southeast Asian countries that are able to provide advanced cellular immunotherapy. The market is fueled by the growing number of cancer cases, which creates an emergency for innovative treatment solutions. The government's allocation of the healthcare budget has shown considerable growth, indicating greater support for advanced medical research. Collaborations and the development of research institutes dedicated to specialized research in the country are accelerating the translation of T-cell therapy from the laboratory to the clinic.

Vietnam T-cell Therapy Market Trends:

Advancement in Domestic CAR-T Cell Manufacturing Capabilities

Vietnam is progressively developing indigenous T-cell therapy manufacturing infrastructure to reduce dependency on imported treatments and lower patient costs. Research institutions are investing in specialized laboratories and cell processing facilities meeting international quality standards. In December 2024, Hoa Lam Shangri-La Healthcare partnered with Japan's Cyto-Facto Inc. to establish Vietnam's first quality control center for stem cell production built to cGMP standards. These developments support Vietnam T-cell therapy market growth by enabling local production capabilities that make advanced treatments more accessible.

Integration of International Treatment Protocols and Clinical Trials

Vietnamese healthcare institutions are increasingly participating in international clinical trials and adopting global treatment protocols for T-cell therapies. This integration facilitates knowledge transfer, enhances medical expertise, and provides patients access to cutting-edge treatments. In December 2024, Tam Anh General Hospital and Tam Anh Research Institute (TAMRI) joined the VISTA-1 trial for RBS2418, an oral immunotherapy targeting advanced colorectal cancer, in collaboration with Stanford University. Such participation strengthens research infrastructure and positions Vietnam as an emerging clinical trial destination for advanced oncology therapeutics.

Expansion of Specialized Oncology Treatment Centers

The establishment and expansion of dedicated oncology centers equipped with advanced immunotherapy capabilities is reshaping Vietnam's cancer treatment landscape. Major hospitals are upgrading facilities and training specialized personnel to deliver cell-based therapies. Ho Chi Minh City Oncology Hospital reported nearly 800,000 patient visits in 2023, highlighting the substantial demand for cancer care services. The hospital has announced plans to establish proton radiotherapy centers and cyclotron radioisotope production facilities, aiming to become a leading cancer treatment hub in Southeast Asia.

Market Outlook 2026-2034:

The market outlook for Vietnam’s T-cell therapy market is highly promising as the country is continuing to invest in infrastructure and research capabilities for advanced cancer treatments. The government’s efforts to promote the development of biotechnology, ease of drug approval, and collaborations with global pharmaceutical companies are expected to accelerate the growth of the market. The focus on lowering the cost of treatment and improving insurance coverage for immunotherapy treatments will further improve accessibility for patients. The market generated a revenue of USD 18.87 Million in 2025 and is projected to reach a revenue of USD 63.72 Million by 2034, growing at a compound annual growth rate of 14.48% from 2026-2034.

Vietnam T-cell Therapy Market Report Segmentation:

Modality Insights:

• Research
• Commercialized

Research dominates with a market share of 74.3% of the total Vietnam T-cell therapy market in 2025.

The research modality is at the forefront of the Vietnam T-cell therapy market, as the nation focuses on research and development of new cellular therapies before mass commercialization. Research institutions and healthcare facilities are working together to further the applications of T-cell therapy through clinical and preclinical research. The Vinmec Research Institute of Stem Cell and Gene Technology has been at the forefront of the research, conducting phase I clinical trials to assess the safety and efficacy of CAR-T cell therapy in patients with CD19-positive refractory or relapsed non-Hodgkin lymphoma or acute lymphoblastic leukemia, with complete remission observed in 87% of patients after treatment.

Research activities are aided by significant government outlay and international collaborations that make technology transfer and expertise building easier. The Ministry of Health's increased budget allocation for healthcare research allows for more clinical research and infrastructure development. Vietnamese institutions are setting up dedicated labs that meet international standards for cell processing and genetic modification. The research work is focused on developing cost-effective treatment protocols that are appropriate for the Vietnamese healthcare setting while ensuring therapeutic efficacy comparable to international standards, thus enabling Vietnam to move promising research outcomes towards commercialization.

Therapy Type Insights:

• CAR T-cell based
•  T Cell Receptor (TCR) based
•  Tumor Infiltrating Lymphocytes (TIL) based

CAR T-cell based leads with a share of 65.0% of the total Vietnam T-cell therapy market in 2025.

CAR T-cell based therapy dominates the Vietnam market due to demonstrated clinical success in treating hematologic malignancies and the established international evidence base supporting its efficacy. This therapy involves genetically modifying patient T-cells to express chimeric antigen receptors that recognize and destroy cancer cells. Vietnam achieved a significant milestone in 2023 when a four-year-old child with acute lymphoblastic leukemia became the first patient in the country successfully treated with CAR-T cell therapy at Vinmec Times City Hospital, achieving complete remission after treatment and demonstrating the viability of this approach in Vietnamese healthcare settings.

The relevance of CAR T-cell therapy is further reinforced by the ongoing initiatives to develop local capabilities for its production and lower the costs of treatment. Local institutions in Vietnam are working on developing technology to independently culture genes and cells, which will lower the costs by a significant margin compared to the current international prices. The Blood Transfusion and Hematology Hospital in Ho Chi Minh City is working on developing the capability to produce CAR-T cells with the aim of lowering the costs of treatment by a factor of about twenty times, from tens of thousands of dollars to less than nineteen thousand dollars per patient.

Indication Insights:

• Hematologic Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma
• Solid Tumors
  • Melanoma
  • Brain and Central Nervous System
  • Liver Cancer
  • Others
• Others

Hematologic malignancies exhibit a clear dominance with a 69.7% share of the total Vietnam T-cell therapy market in 2025.

Hematologic malignancies are the main therapeutic area for T-cell therapy in Vietnam, in line with the international trend, where blood malignancies have shown the best response rates to cellular immunotherapy. Acute lymphoblastic leukemia and lymphomas are the leading targets for CAR-T cell therapy. Children with lymphoblastic leukemia in Vietnam have had poor survival rates compared to international standards, thus creating an urgent need for new therapeutic modalities. The successful treatment of pediatric leukemia patients with CAR-T cell therapy has proven this indication as a high priority area for further development and application in the country.

The leading position of hematologic malignancies in the therapeutic area of T-cell therapy is determined by both efficacy and feasibility considerations for the application of T-cell therapies. Blood malignancies are more attractive targets for engineered T-cells compared to solid tumors, which also have to overcome the barriers of immunosuppressive tumor microenvironments. The specialized expertise in treating blood malignancies has been developed by oncology centers in Vietnam, and specialized hematology departments have been established at K Hospital and the Blood Transfusion and Hematology Hospital.

Regional Insights:

• Northern Vietnam
• Central Vietnam
• Southern Vietnam

Southern Vietnam represents the leading segment with a 49.7% share of the total Vietnam T-cell therapy market in 2025.

Southern Vietnam is at the forefront in the T-cell therapy market due to the presence of sophisticated medical facilities in Ho Chi Minh City, which is the main healthcare hub for the southern part of the country. The Ho Chi Minh City Oncology Hospital is the main treatment center for cancer patients in Southern Vietnam and is a comprehensive hospital with a large number of beds and a high number of patient visits per year.

The region has advantages from international hospitals, private investment in healthcare, and research institutions that enhance cellular therapy. The Blood Transfusion and Hematology Hospital successfully conducted Vietnam's first CAR-T cell therapy on a patient with acute leukemia, indicating that Southern Vietnam is at the forefront of adopting new technologies in healthcare. Collaborations between local hospitals and international pharmaceutical firms make the region the leading location for T-cell therapy development in the country.

Market Dynamics:

Growth Drivers:

Why is the Vietnam T-cell Therapy Market Growing?

Rising Cancer Incidence and Unmet Treatment Needs

There is a rising number of cancer patients in Vietnam, which creates an urgent need for innovative treatment methods such as T-cell therapy. Each year, the country records a high number of new cancer patients and cancer-related deaths, and projections indicate that this is expected to continue in the coming years. The challenge of late-stage cancer diagnosis is also a significant concern, as most patients are diagnosed with late-stage cancer at major cancer hospitals, making it challenging to treat using conventional treatment methods. The aforementioned situation creates a need to explore innovative immunotherapy methods that can help treat resistant patients. Leukemia is among the leading causes of cancer deaths, which creates a specific need for T-cell therapies that have been indicated to be effective in the treatment of hematologic malignancies.

Government Healthcare Investment and Policy Support

The Vietnamese government has put in considerable effort to enhance funding and policies for the development of advanced medical technologies like cellular therapies. The National Biotechnology Development Strategy of the Vietnamese government offers funding for research projects related to biotechnology, including gene therapy and new-generation therapies. The Vietnamese government has also put in effort to simplify the drug approval process, with the revised Law on Pharmacy creating a clearer framework for biological drugs. The scope of health insurance has improved significantly, and there is potential for better access to treatment with new therapies.

International Partnerships and Technology Transfer Initiatives

Strategic collaborations between Vietnamese healthcare institutions and international partners are accelerating T-cell therapy development and adoption. In September 2024, Ho Chi Minh City Oncology Hospital and AstraZeneca Vietnam renewed their partnership agreement through 2027 to enhance cancer care quality, including plans for Vietnam's first Cancer Genetic Counseling Unit. Japanese collaboration has strengthened stem cell quality control capabilities, with Hoa Lam Shangri-La Healthcare partnering with Cyto-Facto to establish cGMP-standard stem cell production facilities. Vietnamese hospitals are participating in international clinical trials, including the VISTA-1 study conducted in collaboration with Stanford University. These partnerships facilitate knowledge transfer, provide access to advanced technologies, and support development of local manufacturing capabilities that reduce treatment costs while maintaining international quality standards.

Market Restraints:

What Challenges the Vietnam T-cell Therapy Market is Facing?

High Treatment Costs and Limited Insurance Coverage

The high cost of T-cell therapy is a major hindrance to its widespread use in Vietnam. The existing health insurance programs in Vietnam do not support the high cost of advanced immunotherapy, and patients have to pay a substantial amount of money from their pockets, which is not affordable by most families.

Infrastructure and Skilled Personnel Limitations

The Vietnamese healthcare infrastructure is challenged by the lack of infrastructure to support the provision of T-cell therapy. The specialized facilities needed for cell processing, genetic modification, and patient care are mainly found in large cities, thus contributing to disparities in access for rural patients. The lack of human resources in the field of cellular therapy manufacturing, administration, and toxicity management hinders the growth of the market.

Regulatory Framework Development Requirements

The current regulatory framework for advanced cellular therapies in Vietnam is still in the process of development and is creating uncertainty regarding the timelines for product development and commercialization. Although recent legislative changes have enhanced the pharmaceutical approval process in Vietnam, guidelines for the manufacturing process, quality control, and application of T-cell therapy are still in the process of development.

Competitive Landscape:

The Vietnam T-cell therapy market is driven by an emerging competitive environment that includes research institutions, specialized hospitals, and global pharmaceutical collaborations. Top hospitals are setting up cell and gene therapy research institutes and upgrading infrastructure. The competition is based on the development of cost-efficient manufacturing processes, technology transfer agreements, and the development of specialized treatment capabilities. Academic hospitals are working in partnership with biotechnology companies to move forward with clinical trials and develop treatment protocols. Strategic hospital and global pharmaceutical company partnerships are accelerating knowledge and product development. Market players are differentiating themselves based on research capabilities, treatment success, cost efficiency, and patient access programs, preparing to capitalize on increasing demand as the market shifts from research-oriented applications to broader clinical uses.

Vietnam T-cell Therapy Market Report Coverage: